2022 World Conference on Lung Cancer (ePosters)-EP08.02-152. Long-Term Survival With Anlotinib in a Patient With Advanced Undifferentiated Large-Cell Lung Cancer and Rare Tonsillar Metastasis

EP08.02-152. Long-Term Survival With Anlotinib in a Patient With Advanced Undifferentiated Large-Cell Lung Cancer and Rare Tonsillar Metastasis

Back to course

Pdf Summary

Researchers in China have highlighted the potential benefits of anlotinib, a small-molecule antiangiogenic tyrosine kinase inhibitor, for patients with advanced undifferentiated large-cell lung cancer. In a case study, a patient with this rare form of cancer, which typically has a poor prognosis and is resistant to chemotherapy, achieved a long survival time with anlotinib treatment after chemotherapy failure. The patient had also developed rare tonsillar metastases.<br /><br />The researchers collected data from next-generation sequencing, imaging, laryngoscopy, and survival records. They also analyzed data from the Surveillance, Epidemiology, and End Results (SEER) database to confirm the survival of undifferentiated large-cell lung cancer. Immunohistochemical analysis was used to explore potential targets for therapy.<br /><br />Their analysis of the SEER database revealed that patients with stage IV undifferentiated large-cell lung cancer typically had a median overall survival of only 4 months, with chemotherapy providing just an additional 5 months. This study documented the first case of advanced large-cell undifferentiated lung cancer with rare tonsillar metastasis. The patient had initially responded to platinum-based systemic chemotherapy and local treatment but developed resistance within 3 months.<br /><br />Anlotinib was then administered to the patient orally after chemotherapy resistance occurred, and the outcome was assessed as continued stable disease. The patient's progression-free survival was noted at 21.5 months, and overall survival at 27.5 months. Retrospective immunohistochemical analysis showed that the patient was positive for one of the targets of anlotinib, PDGFR.<br /><br />Overall, this case study suggests that anlotinib may be an effective option for patients with large-cell undifferentiated lung cancer who have developed resistance to chemotherapy. It also indicates that PDGFR may be the target responsible for this therapeutic effect. Further research and studies are warranted to validate these findings and explore the potential of anlotinib in treating advanced undifferentiated large-cell lung cancer.

Asset Subtitle

Zhaoxia Wang

Meta Tag

Speaker Zhaoxia Wang

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

anlotinib

antiangiogenic

tyrosine kinase inhibitor

advanced undifferentiated large-cell lung cancer

chemotherapy resistance

tonsillar metastases

next-generation sequencing

immunohistochemical analysis

overall survival

PDGFR